First Line Ovarian Cancer Treatment - Cohort Study

Sponsor
ARCAGY/ GINECO GROUP
Study ID
NCT01832415
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Observation of bevacizumab administration in first line ovarian cancer treatment

Study Details

The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of bevacizumab (Avastin ®)

Key Dates

First listed
Apr 16, 2013
Start date
Apr 30, 2013
Status verified
Mar 2016
Primary completion
Feb 28, 2015
Completion
Mar 31, 2016

Study Design

Enrollment
500 participants (actual)

Arms

  • Arm: Use of bevacizumab (Avastin ®) - First-line ovarian cancer
    Patient receiving bevacizumab in ovarian cancer first line treatment

Primary Outcome Measure

Safety according to CTCAE v4.0 criteria [ Time Frame: Patient will be followed dureing 36 months ]

Related Studies